CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience

• Michel Sadelain,
• Eric L Smith,
• Jae H Park,
• Renier J Brentjens,
• Ahmet Dogan,
• Sébastien Monette,
• Isabelle Riviere,
• M Lia Palomba,
• David Qualls,
• Shenon Sethi,
• Mikhail Roshal,
• Brigitte Senechal,
• Xiuyan Wang

Affiliations

Michel Sadelain

Department of Medicine, Division of Cell Therapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Eric L Smith

Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Jae H Park

Department of Medicine, Division of Cell Therapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Renier J Brentjens

Department of Medicine, Division of Cell Therapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Ahmet Dogan

Memorial Sloan Kettering Cancer Center Department of Pathology, New York, New York, USA

Sébastien Monette

Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Isabelle Riviere

Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA

M Lia Palomba

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA

David Qualls

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Shenon Sethi

Memorial Sloan Kettering Cancer Center Department of Pathology, New York, New York, USA

Mikhail Roshal

Memorial Sloan Kettering Cancer Center Department of Pathology, New York, New York, USA

Brigitte Senechal

Department of Medicine, Division of Cell Therapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Xiuyan Wang

Department of Medicine, Division of Cell Therapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA